Biogen Inc. (BIIB Quick QuoteBIIB - Free Report) reported $2.53 billion in revenue for the quarter ended September 2025, representing a year-over-year increase of 2.8%. EPS of $4.81 for the same period compares to $4.08 a year ago.

The reported revenue compares to the Zacks Consensus Estimate of $2.34 billion, representing a surprise of +8.31%. The company delivered an EPS surprise of +23.65%, with the consensus EPS estimate being $3.89.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Biogen performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Revenue- Product- Rare Disease- SKYCLARYS - Rest of World: $58.3 million compared to the $57.78 million average estimate based on 24 analysts. The reported number represents a change of +184.4% year over year.
• Revenue- Product- Multiple Sclerosis (MS)- TYSABRI- Rest of world: $184.3 million versus the 24-analyst average estimate of $156.53 million. The reported number represents a year-over-year change of +3.2%.
• Revenue- Product- Multiple Sclerosis (MS)- TYSABRI- United States: $247.5 million versus the 24-analyst average estimate of $215.01 million. The reported number represents a year-over-year change of +8.8%.
• Revenue- Product- Rare Disease- SPINRAZA- Rest of World: $220.8 million versus the 24-analyst average estimate of $221.37 million. The reported number represents a year-over-year change of -3.3%.
• Revenue- Product- Rare Disease- SKYCLARYS- Total: $132.9 million compared to the $140.9 million average estimate based on 27 analysts. The reported number represents a change of +29.9% year over year.
• Revenue- Product- Multiple Sclerosis (MS)- TYSABRI- Total: $431.8 million versus the 27-analyst average estimate of $369.87 million. The reported number represents a year-over-year change of +6.3%.
• Revenue- Product- Rare Disease- SPINRAZA- Total: $374 million versus the 27-analyst average estimate of $372.83 million. The reported number represents a year-over-year change of -1.9%.
• Revenue- Anti-CD20 therapeutic programs: $493.9 million versus $450.42 million estimated by 26 analysts on average. Compared to the year-ago quarter, this number represents a +10.7% change.
• Revenue- Product, net: $1.85 billion versus $1.71 billion estimated by 26 analysts on average. Compared to the year-ago quarter, this number represents a +4.4% change.
• Revenue- Product- Other- ZURZUVAE- Total: $55.3 million versus the 25-analyst average estimate of $49.62 million.
• Revenue- Product- Multiple Sclerosis (MS)- Fumarate- TECFIDERA- Total: $168.2 million compared to the $158.1 million average estimate based on 25 analysts. The reported number represents a change of -27.8% year over year.
• Revenue- Product- Multiple Sclerosis (MS)- Fumarate- VUMERITY- Total: $214.6 million compared to the $173 million average estimate based on 25 analysts. The reported number represents a change of +35.7% year over year.

View all Key Company Metrics for Biogen here>>>

Shares of Biogen have returned -4.1% over the past month versus the Zacks S&P 500 composite's +3.6% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.